Navigation Links
Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures

LOS GATOS, Calif., Dec. 16 /PRNewswire/ -- TriCipher will host an informative Webinar detailing the cost cutting capabilities of digital signatures for the pharmaceutical and health care industries and strategies for securing digital signatures as more business processes transition online. The one hour webinar on December 16th brings together executives from SAFE- BioPharma Association and Pfizer who will discuss how digital signatures have benefited and streamlined research processes.

"Digital signatures represent the 'last mile' in moving business processes online for the pharmaceutical and health care industries," said Jon Brody, vice president of marketing at TriCipher. "Through the work of industry associations like SAFE-BioPharma and enabling technology companies like TriCipher, it's now possible to bridge that gap."

    Participants that attend the Webinar will learn:

     --   How businesses have saved hundreds of thousands of dollars by no
          longer needing to handle paper-based signatures
     --   The benefits of streamlining submissions to FDA and other regulatory
     --   Strategies for protecting intellectual property and delivering a
          long term solution to IP preservation
     --   The 'Green' benefits of digital signatures

     WHO:      Mollie Shields-Uehling, president and CEO, SAFE-BioPharma
               William Barnes, Director of Identity Services, Pfizer
               Jon Brody, vice president of marketing, TriCipher
               A managing director of identity services at a leading
               international systems integrator
     WHAT:     "Cutting Costs with Digital Signatures in the Biopharmaceutical
     WHEN:     Tuesday, December 16th, 11 a.m. - 12 p.m. PT
     WHERE:    To register please visit:

The webinar will include a brief demonstration of digital signatures using TriCipher's MySignatureBook with SAFE-BioPharma credentials. For more information on MySignatureBook and the webinar, please visit

About TriCipher

TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System(TM) (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Recently, TriCipher introduced myOneLogin(TM) the first secure on-demand offering that delivers strong authentication, single sign-on (SSO) convenience and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in a single solution. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, EPIC Ventures, Intel Capital, RBC Technology Ventures, and Trident Capital. For more information, visit TriCipher on the web at

About MySignatureBook

TriCipher MySignatureBook(TM) is a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document. MySignatureBook ensures end-to-end security for highly regulated and sensitive documents, and eliminates time-consuming and costly paper-based signature processes, including shipping and storage. MySignaureBook supports a range of MSB supports a variety of strong credentials, including TriCipher clientless credentials, SAFE(TM) credentials, TriCipher ID Tool and ID Tool ToGo and any PKCS#11 digital credential. A robust web services interface makes it easy to integrate MSB with a variety of applications and document management systems.

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma(TM) digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, , Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit

SAFE-BioPharma(TM) is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

All product and company names herein may be trademarks of their registered owners.

SOURCE TriCipher, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... PALO ALTO, Calif. (PRWEB) , ... November 25, 2015 , ... ... Beddit Smart and Beddit Classic sleep tracking systems. The new app features a more ... to see and understand how well you slept. The SleepScore is created by a ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, MD, ... the efficacy of its product and its disinfection protocol. This study is taking place ... through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, Illinois. ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number ... first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired ... Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. ...
(Date:11/25/2015)... Md (PRWEB) , ... November 25, 2015 , ... ... Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for ... of this disease. The Periwinkle Pioneers, nominated by the public, will receive special ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... of shareholders held today, the Company,s shareholders voted in ... previously announced agreement and plan of merger (the "Merger ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
(Date:11/24/2015)... 2015 Sectra (STO: SECT B) ... into a multi-year agreement to deploy Breast Imaging ... provide the Breast Center a future-proof platform capable of ... SECT B) announces that Breast Center of Acadiana ... Breast Imaging PACS in its two freestanding imaging centers. This ...
Breaking Medicine Technology: